Reforgene named a 2023 Future Healthcare Top 100 company
The 2023 Seventh Future Healthcare Top 100 conference, themed "Crossing East and West", interpreted the pioneering spirit of healthcare innovation trailblazers. The conference officially opened on May 5 and released the 2023 Future Healthcare Top 100 list on the evening of May 6. Reforgene was selected into the China Innovative Biopharmaceutical TOP100. The selection indicates that Reforgene has been recognized by industry experts, industry observers and analysis institutions in the fields of gene editing technology and drug innovation. Reforgene will continue to be driven by technological innovation and promote its growth into a globally competitive biotechnology enterprise.
About the 2023 Future Healthcare Top 100
Founded in 2015 by VB100, VBDATA and Danke Research Institute, the Future Healthcare Top 100 list is the first domestic list for innovative healthcare companies targeting non-listed enterprises. It aims to select Chinese innovative healthcare providers that truly represent the future of healthcare, discover the core strength of China's future healthcare industry, and promote the innovation and transformation of the health industry. Over seven years, the Future Healthcare Top 100 selection system has been continuously enriched, gradually building a global innovative healthcare selection ecosystem for enterprises, investment institutions and industrial parks, and extending to innovative product and innovative technology selections.
This selection is open to non-listed enterprises in the healthcare field. Based on the VB100 value evaluation model, through the process of enterprise self-application, VB100 review committee evaluation, cross-review by supporting institutions and final review by the expert committee, it selects the TOP100 innovative enterprises by valuation from five major fields (medical devices/biomedicine/digital healthcare/medical services/business and supply chain services). Beyond valuation, it also examines the growth and annual performance of candidate enterprises across four first-level indicators, namely human resources, knowledge resources, key partner resources and market performance, totaling 17 second-level indicators.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.